Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2009-09-02

Clinical Trial Update: Rebif New Formulation (RNF) Quality of Life (QOL) Study [Phase 3]

View source ↗

Summary

Phase 3 study evaluating Rebif New Formulation (RNF) for quality of life in relapsing multiple sclerosis; completed with results posted in 2009.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Rebif (interferon beta-1a)

Snippet

Sponsor: EMD Serono | Conditions: Relapsing Multiple Sclerosis | Phase 3 | Status: COMPLETED | Results posted: 2009-09-02